NASDAQ:GNMK - GenMark Diagnostics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $6.67 0.00 (0.00 %) (As of 05/24/2019 04:00 PM ET)Previous Close$6.67Today's Range$6.62 - $6.8352-Week Range$3.58 - $8.81Volume92,272 shsAverage Volume351,463 shsMarket Capitalization$380.38 millionP/E RatioN/ADividend YieldN/ABeta1.55 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It also provides diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, thrombophilia risk test, a warfarin sensitivity test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test. The company sells its products through direct sales and technically specialized service organization in the United States and Europe. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California. Receive GNMK News and Ratings via Email Sign-up to receive the latest news and ratings for GNMK and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GNMK Previous Symbol CUSIPN/A CIK1487371 Webhttp://www.genmarkdx.com/ Phone760-448-4300Debt Debt-to-Equity Ratio1.96 Current Ratio3.93 Quick Ratio3.40Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$70.76 million Price / Sales5.38 Cash FlowN/A Price / Cash FlowN/A Book Value$0.43 per share Price / Book15.51Profitability EPS (Most Recent Fiscal Year)($0.91) Net Income$-50,500,000.00 Net Margins-71.40% Return on Equity-137.04% Return on Assets-54.05%Miscellaneous Employees477 Outstanding Shares57,029,000Market Cap$380.38 million Next Earnings Date7/29/2019 (Estimated) OptionableOptionable GenMark Diagnostics (NASDAQ:GNMK) Frequently Asked Questions What is GenMark Diagnostics' stock symbol? GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK." How were GenMark Diagnostics' earnings last quarter? GenMark Diagnostics, Inc (NASDAQ:GNMK) issued its quarterly earnings data on Tuesday, April, 30th. The medical equipment provider reported ($0.21) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.20) by $0.01. The medical equipment provider had revenue of $21.53 million for the quarter, compared to analysts' expectations of $21.08 million. GenMark Diagnostics had a negative net margin of 71.40% and a negative return on equity of 137.04%. View GenMark Diagnostics' Earnings History. When is GenMark Diagnostics' next earnings date? GenMark Diagnostics is scheduled to release their next quarterly earnings announcement on Monday, July 29th 2019. View Earnings Estimates for GenMark Diagnostics. What guidance has GenMark Diagnostics issued on next quarter's earnings? GenMark Diagnostics issued an update on its FY 2019 earnings guidance on Tuesday, April, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $85-90 million, compared to the consensus revenue estimate of $86.86 million. What price target have analysts set for GNMK? 4 analysts have issued 12-month target prices for GenMark Diagnostics' shares. Their predictions range from $7.00 to $12.00. On average, they anticipate GenMark Diagnostics' share price to reach $9.6667 in the next twelve months. This suggests a possible upside of 44.9% from the stock's current price. View Analyst Price Targets for GenMark Diagnostics. What is the consensus analysts' recommendation for GenMark Diagnostics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GenMark Diagnostics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GenMark Diagnostics. What are Wall Street analysts saying about GenMark Diagnostics stock? Here are some recent quotes from research analysts about GenMark Diagnostics stock: 1. According to Zacks Investment Research, "GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor® XT-8 system is the second generation in GenMark Dx's eSensor® platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California. " (5/21/2019) 2. Canaccord Genuity analysts commented, "We are positive on the hire of the role of SVP of Sales, adding to the company’s management team. GenMark is well positioned to execute this year as the sales force now has the new trio" of blood culture ID panels to sell. We reiterate our BUY rating and $10 price target. Q1 was a slight beat – impressive given tough Y/Y comp. Q1 revs of $21.5M (+4% Y/ Y) beat our $20.7M (flat $20.9M, which we view as solid particularly given a very difficult comp due to last year’s record influenza season. GNMK placed 39 net ePlex instruments, above our 34E. LPS of ($0.21) matched us and was in line with Street’s ($0.20). OPEX of $16.8M (+12% Y/Y) was consistent with our $16.2M. Reiterates 2019 revenue/placement guide." (5/1/2019) 3. Needham & Company LLC analysts commented, "GNMK’s 4Q18 revenue was consistent with its preannouncement while its EPS missed consensus. Management provided 2019 revenue guidance that was above consensus at the mid-point and ePlex placement guidance that was above our estimate at the mid-point. GNMK placed 42 ePlex systems in 4Q18, down from 45 in 3Q18 but above our estimate of 39. We believe the 4Q18 results provide further evidence that ePlex is gaining momentum while GNMK works out its manufacturing growing pains. We think an expanding test menu should help drive ePlex placements and utilization 2019 and we reiterate our Buy rating." (2/22/2019) Has GenMark Diagnostics been receiving favorable news coverage? Media headlines about GNMK stock have trended positive recently, InfoTrie reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. GenMark Diagnostics earned a coverage optimism score of 2.3 on InfoTrie's scale. They also gave news articles about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future. Who are some of GenMark Diagnostics' key competitors? Some companies that are related to GenMark Diagnostics include Silk Road Medical (SILK), Cardiovascular Systems (CSII), K2M Group (KTWO), AtriCure (ATRC), Cryolife (CRY), Orthofix Medical (OFIX), Luminex (LMNX), Tactile Systems Technology (TCMD), Axonics Modulation Technologies (AXNX), Intersect ENT (XENT), AngioDynamics (ANGO), Cerus (CERS), Orthopediatrics (KIDS), Anika Therapeutics (ANIK) and SurModics (SRDX). What other stocks do shareholders of GenMark Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other GenMark Diagnostics investors own include Mattel (MAT), Ultra Clean (UCTT), General Electric (GE), Alibaba Group (BABA), Twitter (TWTR), US Foods (USFD), American National BankShares (AMNB), Enterprise Bancorp (EBTC), CLEAR CHANNEL O/SH (CCO) and New York Times (NYT). Who are GenMark Diagnostics' key executives? GenMark Diagnostics' management team includes the folowing people: Mr. Hany Massarany, CEO, Pres & Director (Age 58)Mr. Scott Mendel, Chief Operating Officer (Age 52)Mr. Michael Gleeson, Sr. VP of Corp. Accounts (Age 44)Mr. John Frederick Ek, Chief Financial Officer (Age 43)Mr. Eric Stier, Sr. VP, Gen. Counsel & Sec. (Age 43) Who are GenMark Diagnostics' major shareholders? GenMark Diagnostics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.85%), Cadian Capital Management LP (9.03%), BlackRock Inc. (6.34%), HighTower Advisors LLC (4.45%), JPMorgan Chase & Co. (4.04%) and Assenagon Asset Management S.A. (1.36%). Company insiders that own GenMark Diagnostics stock include Brian Andrew Mitchell, Eric Stier, Hany Massarany, James B Mcnally, Jennifer Anne Williams, John Frederick Ek, Jon Faiz Kayyem, Michael Gleeson, Michael Kagnoff, Scott Mendel and Tyler Jensen. View Institutional Ownership Trends for GenMark Diagnostics. Which major investors are selling GenMark Diagnostics stock? GNMK stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Penn Capital Management Co. Inc., Northern Trust Corp, BlackRock Inc., OLD National Bancorp IN, TD Asset Management Inc., Wrapmanager Inc. and Jefferies Group LLC. Company insiders that have sold GenMark Diagnostics company stock in the last year include Brian Andrew Mitchell, Eric Stier, Hany Massarany, James B Mcnally, John Frederick Ek, Michael Gleeson, Scott Mendel and Tyler Jensen. View Insider Buying and Selling for GenMark Diagnostics. Which major investors are buying GenMark Diagnostics stock? GNMK stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Oxford Asset Management LLP, HighTower Advisors LLC, Cadian Capital Management LP, Man Group plc, Assenagon Asset Management S.A., Morgan Stanley and Renaissance Technologies LLC. View Insider Buying and Selling for GenMark Diagnostics. How do I buy shares of GenMark Diagnostics? Shares of GNMK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is GenMark Diagnostics' stock price today? One share of GNMK stock can currently be purchased for approximately $6.67. How big of a company is GenMark Diagnostics? GenMark Diagnostics has a market capitalization of $380.38 million and generates $70.76 million in revenue each year. The medical equipment provider earns $-50,500,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. GenMark Diagnostics employs 477 workers across the globe. What is GenMark Diagnostics' official website? The official website for GenMark Diagnostics is http://www.genmarkdx.com/. How can I contact GenMark Diagnostics? GenMark Diagnostics' mailing address is 5964 LA PLACE COURT, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-448-4300 or via email at [email protected] MarketBeat Community Rating for GenMark Diagnostics (NASDAQ GNMK)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 412 (Vote Outperform)Underperform Votes: 252 (Vote Underperform)Total Votes: 664MarketBeat's community ratings are surveys of what our community members think about GenMark Diagnostics and other stocks. Vote "Outperform" if you believe GNMK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: Quiet Period Expirations Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.